Effect of HSV-2 suppressive therapy on genital tract HIV-1 RNA shedding among women on HAART: A pilot randomized controlled trial

A. E. Nijhawan, A. K. Delong, S. Chapman, A. Rana, J. Kurpewski, J. Ingersoll, A. M. Caliendo, S. Cu-Uvin

Research output: Contribution to journalArticle

Abstract

Background. The role of suppressive HSV therapy in women coinfected with HSV-2 and HIV-1 taking highly active antiretroviral therapy (HAART) is unclear. Methods. 60 women with HIV-1/HSV-2 coinfection on HAART with plasma HIV-1 viral load (PVL) ≤75 copies/mL were randomized to receive acyclovir (N = 30) or no acyclovir (N = 30). PVL, genital tract (GT) HIV-1, and GT HSV were measured every 4 weeks for one year. Results. Detection of GT HIV-1 was not significantly different in the two arms (OR 1.23, P = 0.67), although this pilot study was underpowered to detect this difference. When PVL was undetectable, the odds of detecting GT HIV were 0.4 times smaller in the acyclovir arm than in the control arm, though this was not statistically significant (P = 0.07). The odds of detecting GT HSV DNA in women receiving acyclovir were significantly lower than in women in the control group, OR 0.38, P < 0.05. Conclusions. Chronic suppressive therapy with acyclovir in HIV-1/HSV-2-positive women on HAART significantly reduces asymptomatic GT HSV shedding, though not GT HIV shedding or PVL. PVL was strongly associated with GT HIV shedding, reinforcing the importance of HAART in decreasing HIV sexual transmission.

Original languageEnglish (US)
Article number868526
JournalInfectious Diseases in Obstetrics and Gynecology
Volume2012
DOIs
StatePublished - 2012

Fingerprint

Human Herpesvirus 2
Highly Active Antiretroviral Therapy
HIV-1
Randomized Controlled Trials
RNA
Acyclovir
Viral Load
HIV
Therapeutics
Coinfection
Control Groups

ASJC Scopus subject areas

  • Obstetrics and Gynecology
  • Infectious Diseases
  • Dermatology

Cite this

Effect of HSV-2 suppressive therapy on genital tract HIV-1 RNA shedding among women on HAART : A pilot randomized controlled trial. / Nijhawan, A. E.; Delong, A. K.; Chapman, S.; Rana, A.; Kurpewski, J.; Ingersoll, J.; Caliendo, A. M.; Cu-Uvin, S.

In: Infectious Diseases in Obstetrics and Gynecology, Vol. 2012, 868526, 2012.

Research output: Contribution to journalArticle

Nijhawan, A. E. ; Delong, A. K. ; Chapman, S. ; Rana, A. ; Kurpewski, J. ; Ingersoll, J. ; Caliendo, A. M. ; Cu-Uvin, S. / Effect of HSV-2 suppressive therapy on genital tract HIV-1 RNA shedding among women on HAART : A pilot randomized controlled trial. In: Infectious Diseases in Obstetrics and Gynecology. 2012 ; Vol. 2012.
@article{792c9a87af74417cab3b8b1d16c00e5d,
title = "Effect of HSV-2 suppressive therapy on genital tract HIV-1 RNA shedding among women on HAART: A pilot randomized controlled trial",
abstract = "Background. The role of suppressive HSV therapy in women coinfected with HSV-2 and HIV-1 taking highly active antiretroviral therapy (HAART) is unclear. Methods. 60 women with HIV-1/HSV-2 coinfection on HAART with plasma HIV-1 viral load (PVL) ≤75 copies/mL were randomized to receive acyclovir (N = 30) or no acyclovir (N = 30). PVL, genital tract (GT) HIV-1, and GT HSV were measured every 4 weeks for one year. Results. Detection of GT HIV-1 was not significantly different in the two arms (OR 1.23, P = 0.67), although this pilot study was underpowered to detect this difference. When PVL was undetectable, the odds of detecting GT HIV were 0.4 times smaller in the acyclovir arm than in the control arm, though this was not statistically significant (P = 0.07). The odds of detecting GT HSV DNA in women receiving acyclovir were significantly lower than in women in the control group, OR 0.38, P < 0.05. Conclusions. Chronic suppressive therapy with acyclovir in HIV-1/HSV-2-positive women on HAART significantly reduces asymptomatic GT HSV shedding, though not GT HIV shedding or PVL. PVL was strongly associated with GT HIV shedding, reinforcing the importance of HAART in decreasing HIV sexual transmission.",
author = "Nijhawan, {A. E.} and Delong, {A. K.} and S. Chapman and A. Rana and J. Kurpewski and J. Ingersoll and Caliendo, {A. M.} and S. Cu-Uvin",
year = "2012",
doi = "10.1155/2012/868526",
language = "English (US)",
volume = "2012",
journal = "Infectious Diseases in Obstetrics and Gynecology",
issn = "1064-7449",
publisher = "Hindawi Publishing Corporation",

}

TY - JOUR

T1 - Effect of HSV-2 suppressive therapy on genital tract HIV-1 RNA shedding among women on HAART

T2 - A pilot randomized controlled trial

AU - Nijhawan, A. E.

AU - Delong, A. K.

AU - Chapman, S.

AU - Rana, A.

AU - Kurpewski, J.

AU - Ingersoll, J.

AU - Caliendo, A. M.

AU - Cu-Uvin, S.

PY - 2012

Y1 - 2012

N2 - Background. The role of suppressive HSV therapy in women coinfected with HSV-2 and HIV-1 taking highly active antiretroviral therapy (HAART) is unclear. Methods. 60 women with HIV-1/HSV-2 coinfection on HAART with plasma HIV-1 viral load (PVL) ≤75 copies/mL were randomized to receive acyclovir (N = 30) or no acyclovir (N = 30). PVL, genital tract (GT) HIV-1, and GT HSV were measured every 4 weeks for one year. Results. Detection of GT HIV-1 was not significantly different in the two arms (OR 1.23, P = 0.67), although this pilot study was underpowered to detect this difference. When PVL was undetectable, the odds of detecting GT HIV were 0.4 times smaller in the acyclovir arm than in the control arm, though this was not statistically significant (P = 0.07). The odds of detecting GT HSV DNA in women receiving acyclovir were significantly lower than in women in the control group, OR 0.38, P < 0.05. Conclusions. Chronic suppressive therapy with acyclovir in HIV-1/HSV-2-positive women on HAART significantly reduces asymptomatic GT HSV shedding, though not GT HIV shedding or PVL. PVL was strongly associated with GT HIV shedding, reinforcing the importance of HAART in decreasing HIV sexual transmission.

AB - Background. The role of suppressive HSV therapy in women coinfected with HSV-2 and HIV-1 taking highly active antiretroviral therapy (HAART) is unclear. Methods. 60 women with HIV-1/HSV-2 coinfection on HAART with plasma HIV-1 viral load (PVL) ≤75 copies/mL were randomized to receive acyclovir (N = 30) or no acyclovir (N = 30). PVL, genital tract (GT) HIV-1, and GT HSV were measured every 4 weeks for one year. Results. Detection of GT HIV-1 was not significantly different in the two arms (OR 1.23, P = 0.67), although this pilot study was underpowered to detect this difference. When PVL was undetectable, the odds of detecting GT HIV were 0.4 times smaller in the acyclovir arm than in the control arm, though this was not statistically significant (P = 0.07). The odds of detecting GT HSV DNA in women receiving acyclovir were significantly lower than in women in the control group, OR 0.38, P < 0.05. Conclusions. Chronic suppressive therapy with acyclovir in HIV-1/HSV-2-positive women on HAART significantly reduces asymptomatic GT HSV shedding, though not GT HIV shedding or PVL. PVL was strongly associated with GT HIV shedding, reinforcing the importance of HAART in decreasing HIV sexual transmission.

UR - http://www.scopus.com/inward/record.url?scp=84858132497&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84858132497&partnerID=8YFLogxK

U2 - 10.1155/2012/868526

DO - 10.1155/2012/868526

M3 - Article

C2 - 22505800

AN - SCOPUS:84858132497

VL - 2012

JO - Infectious Diseases in Obstetrics and Gynecology

JF - Infectious Diseases in Obstetrics and Gynecology

SN - 1064-7449

M1 - 868526

ER -